OncoMatch/Clinical Trials/NCT05338658
Study of PAT in Patients With Solid Tumor Cancers
Is NCT05338658 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Peptide Alarm Therapy (PAT) for metastasis.
Treatment: Peptide Alarm Therapy (PAT) — This is a single center Phase I study with extension of peptide alarm therapy (PAT) administered by intratumoral (IT) injection during the 1st course of a standard of care intravenous PD-1/PD-L1 inhibitor for the treatment of locally advanced or metastatic solid tumor cancers that has failed to be controlled after one or more prior therapies including a previous PD-1/PD-L1 inhibitor
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: HLA-A A*0201 allele
Must have at least one HLA-A*0201 allele
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Cardiac function
new york heart association (nyha) functional classification class i
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Masonic Cancer Center at University of Minnesota · Minneapolis, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05338658 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require HLA-A?
Yes, HLA-A A*0201 allele is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify